The Use of High Dose Letrozole in Ovulation Induction and Controlled Ovarian Hyperstimulation
Author(s) -
Elizabeth A. Pritts,
Alexander K. Yuen,
Shefaali Sharma,
Robert Genisot,
David L. Olive
Publication year - 2011
Publication title -
isrn obstetrics and gynecology
Language(s) - English
Resource type - Journals
eISSN - 2090-4444
pISSN - 2090-4436
DOI - 10.5402/2011/242864
Subject(s) - letrozole , aromatase inhibitor , controlled ovarian hyperstimulation , ovulation , medicine , ovulation induction , follicular phase , randomized controlled trial , aromatase , gynecology , urology , in vitro fertilisation , pregnancy , biology , hormone , breast cancer , cancer , genetics
Letrozole, an aromatase inhibitor, has been demonstrated to be effective as an ovulation induction and controlled ovarian hyperstimulation agent. However, dose administration has generally been limited to 5 days at 2.5 to 7.5 mg daily. We undertook a retrospective review of over 900 treatment cycles using letrozole in doses as high as 12.5 mg per day. Results indicate that such doses do indeed offer benefit to patients; in that there is increased follicular growth and a higher number of predicted ovulations with higher doses of the drug. However, increasing doses does not produce a detrimental effect upon endometrial thickness. High-dose letrozole may be of value in women who fail to respond adequately to lower doses. Furthermore, randomized trials are needed to determine whether high-dose letrozole might actually be optimal as a starting dose for certain treatment groups.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom